Voyager Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
VY-AADC for advanced Parkinson’s disease on track for start of planned global, pivotal Phase 2-3 program during the middle of this year Two IND filings expected from the ALS, Huntington’s disease and Friedreich’s ataxia programs for 2019 Recent AbbVie …